Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Paresh Dandona, Chantal Mathieu, Moshe Phillip, et al.·2017·The Lancet Diabetes & Endocrinology